RecruitingNCT06655090

Fibrotic Interstitial Lung Disease Early Recognition and Strategic Therapy Study in China


Sponsor

Dai Huaping

Enrollment

10,000 participants

Start Date

Dec 1, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

This project aimed to: 1) construct a cohort of no less than 10000 cases of f-ILD (including pneumoconiosis ≥3000 cases) with continuous regular follow-up to reveal the clinical phenotypes closely related to the development, progression and prognosis of pulmonary fibrosis; 2) systematically evaluate the safety and effectiveness of frozen lung biopsy, surgical lung biopsy/thoracoscopic lung biopsy and other techniques, and to optimize the histological diagnosis method of f-ILD; 3) construct a set of artificial intelligence (AI) evaluation system for quantitative evaluation of pulmonary fibrosis and its severity, and develop application software; 4) excavate and verify important molecular targets for the formation of pulmonary fibrosis and identify biomarkers; 5) combined with clinical phenotype, imaging, pathology and biomarkers to establish f-ILD early recognition and progress model, intervention strategies, guidelines and consensus, and applicated nationwide.


Eligibility

Inclusion Criteria1

  • Diagnosed as ILD

Exclusion Criteria2

  • Lack of chest CT
  • Patients refused to participant

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

China-Japan Friendship Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06655090


Related Trials